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Pseudomonas aeruginosa is naturally resistant to many antibiotics, and infections caused by this organism are
a serious threat, especially to hospitalized patients. The intrinsic low permeability of P. aeruginosa to antibi-
otics results from the coordinated action of several mechanisms, such as the presence of restrictive porins and
the expression of multidrug efflux pump systems. Our goal was to develop antimicrobial peptides with an
improved bacterial membrane-permeabilizing ability, so that they enhance the antibacterial activity of anti-
biotics. We carried out a structure activity relationship analysis to investigate the parameters that govern the
permeabilizing activity of short (8- to 12-amino-acid) lactoferricin-derived peptides. We used a new class of
constitutional and sequence-dependent descriptors called PEDES (peptide descriptors from sequence) that allowed
us to predict (Spearman’s   0.74; P < 0.001) the permeabilizing activity of a new peptide generation. To study
if peptide-mediated permeabilization could neutralize antibiotic resistance mechanisms, the most potent peptides
were combined with antibiotics, and the antimicrobial activities of the combinations were determined on P.
aeruginosa strains whose mechanisms of resistance to those antibiotics had been previously characterized. A
subinhibitory concentration of compound P2-15 or P2-27 sensitized P. aeruginosa to most classes of antibiotics
tested and counteracted several mechanisms of antibiotic resistance, including loss of the OprD porin and over-
expression of several multidrug efflux pump systems. Using a mouse model of lethal infection, we demonstrated that
whereas P2-15 and erythromycin were unable to protect mice when administered separately, concomitant admin-
istration of the compounds afforded long-lasting protection to one-third of the animals.
The increasing emergence of antibiotic-resistant bacteria is a
major public health problem. Whereas therapeutic options for
the treatment of infections due to Gram-positive bacteria (e.g.,
methicillin-resistant Staphylococcus aureus [MRSA]) are in ex-
pansion, there is an urgent need for the development of new
drugs effective against Gram-negative pathogens. The latter or-
ganisms, in particular, Pseudomonas aeruginosa, Acinetobacter
baumannii, Stenotrophomonas maltophilia, and several members
of the Enterobacteriaceae, are rapidly evolving resistance to most
of the currently available antibiotic treatments (37).
The resistance of Gram-negative bacteria to antibiotics is
highly dependent on the integrity of the outer membrane (OM),
since this structure acts as a permeability barrier and efficiently
prevents many antimicrobial compounds from reaching their tar-
gets inside the cell (9). In addition, key mechanisms of resistance,
such as antibiotic removal via efflux pump systems, rely on the
ability of the OM to maintain concentrations of drugs in the
periplasm at levels nontoxic for the cell (42). In turn, the OM
owes many of its properties, including its low intrinsic permeabil-
ity, to an external layer composed primarily of a negatively
charged molecule called lipopolysaccharide (LPS). Stability of the
OM depends to a large extent on the cross-bridging of neighbor-
ing LPS molecules by divalent cations (41).
Due to the essential role of LPS in OM stability and the
structural conservation of this molecule in different species of
Gram-negative bacteria, virtually all cellular organisms pro-
duce antibacterial agents targeting LPS. The most prominent
example of these agents belongs to a family called host defense
peptides or antimicrobial peptides (AMPs) (27). The cationic
nature and amphiphilic structure characteristic of the vast ma-
jority of AMPs enable them to bind specifically to LPS, desta-
bilize the OM, and kill the target cell by mechanisms that are
still a matter of debate (6, 38). However, it is clear (at least for
some AMPs) that when added at concentrations lower than
their MICs, they alter the bacterial cell permeability barrier,
thus making bacteria sensitive to agents that would be ex-
cluded by an intact outer membrane (54, 60).
Our model organism is Pseudomonas aeruginosa, one of the
leading causative agents of infections in hospital settings. The
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intrinsic low permeability of the P. aeruginosa OM (at least 10
times lower than that of E. coli [see reference 19]), combined
with the activity of efflux pumps of the Mex family and beta-
lactamase expression (AmpC), confers to this pathogen its
characteristic broad spectrum of antibiotic resistance (39).
Moreover, P. aeruginosa often mutates and gives rise to strains
with enhanced antibiotic resistance due to overexpression of
efflux pumps, acquisition of plasmid-borne metallo-beta-lacta-
mases (MBLs), and repression of the OprD porin (the uptake
pathway for hydrophilic carbapenems, such as imipenem) (5).
Consequently, some isolates of P. aeruginosa remain sensitive
only to polymyxins, although the systemic use of these AMPs is
not widely accepted by clinicians due to their alleged nephro-
and neurotoxicity (35).
We have previously demonstrated that subinhibitory con-
centrations of synthetic peptides derived from lactoferrin, a
human protein with antibacterial and LPS binding activities,
sensitize P. aeruginosa to both hydrophobic and hydrophilic
antibiotics in vitro (53). Although other researchers have re-
ported similar findings using either polymyxin B (PMB) non-
apeptide (PMBN; an enzymatic derivative of PMB) (43, 59) or
other polycations (3, 33, 36, 46, 52, 56, 61), no one has studied
whether OM-permeabilizing peptides share common struc-
tural features not necessarily related to their antibacterial ac-
tivity. In this respect, it is important to point out that good
permeabilizers do not necessarily correspond to compounds
with potent bactericidal activity (53). To the contrary, it has
been reported that those activities are inversely correlated in
some instances (56, 64), suggesting that at least for some
classes of AMPs, OM permeabilization and bactericidal activ-
ity may have different structural bases.
In this work, we designed a novel type of antimicrobial
peptide descriptors for lactoferrin-derived peptides and per-
formed a quantitative structure activity relationship (QSAR)
analysis to predict the permeabilizing activity of a new peptide
generation. We demonstrated that the most potent peptide
from this new library enhances antibiotic activity in vivo and, as
a consequence, confers protection to an animal model of lethal
P. aeruginosa infection. This work sets the foundation for the
rational design of improved lactoferrin-derived permeabilizers
that could act synergistically with antibiotics and neutralize
resistance mechanisms.
MATERIALS AND METHODS
Bacterial strains. All the strains were grown at 37°C in LB (Luria-Bertani
broth; Pronadisa, Madrid, Spain) or TSB (tryptic soy broth; BioMe´rieux, Marcy
l’Etoile, France) supplemented with agar (Pronadisa, Alcobendas-Madrid,
Spain) when necessary. Strains used in the present study are listed in Table 1.
Peptides. Peptides, purchased from PolyPeptide Laboratories (San Diego,
CA), were synthesized with an amidated C terminus using 9-fluorenylmethyloxy-
carbonyl (Fmoc) solid-phase chemistry and were purified by reverse-phase high-
pressure liquid chromatography (RP-HPLC). Purity (96%) and identity were
verified by RP-HPLC and mass spectroscopy analyses. Peptides sequences are
shown in the tables (Table 2; see Table 4).
Antibiotics. Antibiotic solutions were diluted and stored by following the
manufacturer’s recommendations. The antibiotics used were ampicillin, cefo-
taxime, chloramphenicol, erythromycin, fusidic acid, nalidixic acid, novobiocin,
polymyxin B (PMB), polymyxin B nonapeptide (PMBN), tetracycline, and ticar-
cillin (Sigma-Aldrich, Madrid, Spain); amoxicillin and ciprofloxacin (Fluka, Ma-
drid, Spain); meropenem (Meronem; AstraZeneca, Bilbao, Spain); and imi-
penem (Tienam; MSD, Madrid, Spain).
Susceptibility assays. MICs of the peptides were determined in Mueller-
Hinton (MH) medium (Difco Laboratories, Detroit, Michigan) by the broth
microdilution assay by following the recommendations of the Clinical Laboratory
Standards Institute (CLSI; formerly NCCLS) (40), as described elsewhere (53).
Synergy studies. The existence of synergistic interactions between peptides
and antibiotics was assessed by the checkerboard assay (13, 53), using Mueller-
Hinton medium (Difco Laboratories). The fractional inhibitory concentration
(FIC) index of each combination was calculated according to the following formula:
[(A)/MICA]  [(P)/MICP]  FICA  FICP  FIC index, where MICA and MICP
are the MICs of the antibiotic and peptide, respectively, determined separately and
(A) and (P) are the MICs of the antibiotic and peptide, respectively, determined in
combination.
Combinations were classified as synergistic (FIC  0.5), indifferent (0.5 
FIC  4), and antagonist (FIC  4). For those organisms resistant to the highest
concentration tested, the MIC was arbitrarily assigned a value double of that
concentration.
TABLE 1. Characterization of some relevant mechanisms of antibiotic resistance in the P. aeruginosa strains used in this study
Strain Relevant feature(s) Source/reference
Expression of efflux pump systema Other mechanisms
MexAB-
OprM
MexCD-
OprJ
MexEF-
OprN
MexXY-
OprM OprD
b QRDR
modificationsc Carb
d AmpCe Colf
PAO1 Wild type CECTg         
PAOLC1-6 nalB derivative of PAO1 53         
TNP004 OprD derivative of PAO1 53a         
Ps1 Wild type, clinical isolate CUNh         
Ps2 Wild type, clinical isolate CUN        NDi 
Ps4 Wild type, clinical isolate CUN        ND 
Ps6 Wild type, clinical isolate CUN        ND 
Ps21 Wild type, clinical isolate CUN      ND   
Ps64 Wild type, clinical isolate CUN      ND  ND 
Ps71 Wild type, clinical isolate CUN      ND   
Ps74 Wild type, clinical isolate CUN      ND   
a Measured by reverse-transcription PCR (RT-PCR) and Western blotting. “,” “,” and “” denote the presence of basal, intermediate, and high levels of
expression of the indicated efflux pump systems, respectively.
b The presence () or absence () of the OprD porin was assessed by RT-PCR and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).
c The presence () or absence () of mutations in the QRDRs of genes gyrA and parC was detected by sequencing.
d Expression of carbapenemases (Carb) () was quantified by both phenotypic and molecular methods, as described in Materials and Methods.
e Inducible () or constitutive () AmpC expression was assessed by measuring the hydrolysis of cephalothin.
f Resistance to colistin (Col).
g CECT, Coleccio´n Espan˜ola de Cultivos Tipo (Spanish Culture Type Collection).
h Isolated at the Clı´nica Universidad de Navarra (CUN; University Hospital of Navarra).
i ND, not done.
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TABLE 2. Novobiocin-enhancing activity of first-generation peptides on P. aeruginosa Ps4
Peptide Sequence MIC(g/ml)a
Novobiocin MIC at indicated peptide
concn (g/ml) FICb MICratioc
0 6.25 12.5 25 50
LF11 F Q W Q R N I R K V R -NH2 250 1,024 256 256 256 256 0.5 0
C12LF11 lauryl F Q W Q R N I R K V R -NH2 250 1,024 256 256 256 256 0.5 0
P1-1 F W Q R N I R K V R -NH2 250 1,024 256 256 256 256 0.5 0
P1-2 F W Q R I R K V R -NH2 250 512 256 256 128 32 0.262 16
P1-3 F W R N I R K V R -NH2 250 512 256 256 256 256 0.5 2
P1-4 F W Q R N I R V R -NH2 250 1,024 256 256 256 256 0.5 0
P1-5 F W Q R N I K V R -NH2 250 1,024 256 256 256 256 0.5 0
P1-6 F W R I R K V R -NH2 250 512 256 256 128 32 0.262 16
P1-7 F W Q R N I R K V R R -NH2 250 512 256 256 256 64 0.325 8
P1-8 F W Q R N I R K V K K -NH2 250 512 256 256 128 64 0.225 8
P1-9 F W Q R N I R K V R R R -NH2 250 512 256 256 128 64 0.225 8
P1-10 F W Q R N I R K V K K K -NH2 250 512 256 128 32 32 0.113 16
P1-11 F W Q R N I R K V R R R R -NH2 250 512 256 256 128 64 0.325 8
P1-12 F W Q R N I R K V R R R I -NH2 250 512 256 256 64 32 0.225 16
P1-13 F W Q R N I R K V K K K K -NH2 250 512 256 256 128 64 0.225 8
P1-14 F W Q R N I R K V K K K I -NH2 250 1,024 256 128 64 32 0.113 32
P1-15 F W Q R R I R K V R R -NH2 250 512 256 128 32 8 0.163 64
P1-16 F W Q R K I R K V K K -NH2 250 512 256 256 128 64 0.225 8
P1-17 R F W Q R N I R K V R R -NH2 250 512 256 256 256 256 0.5 2
P1-18 K W Q R N I R K V R R -NH2 250 512 256 256 128 64 0.225 8
P1-19 R W Q R N I R K V R R -NH2 250 512 256 256 128 32 0.263 16
P1-20 R R W Q R N I R K V R R -NH2 250 512 256 256 64 32 0.163 16
P1-21 R F W Q R N I R K Y R -NH2 250 512 256 256 256 128 0.350 4
P1-22 R F R W Q R N I R K Y R R -NH2 31.25 1,024 256 32 1 NC 0.431 1,024
P1-23 R W Q R N I R K Y R R -NH2 250 1,024 256 256 256 64 0.263 16
P1-24 R R W Q R N I R K Y R R -NH2 250 1,024 256 256 128 32 0.131 32
P1-25 C F W Q R N I R K V R C -NH2 250 1,024 256 256 256 256 0.5 0
P1-26 C F W Q R N I R K V C R -NH2 250 1,024 256 256 256 256 0.5 0
P1-27 C W Q R N I R K C R -NH2 250 1,024 256 256 256 256 0.5 0
P1-28 C F W Q R N I R K V R C -NH2 250 1,024 256 256 256 256 0.5 0
P1-29 F W Q R N I R K I R -NH2 250 1,024 256 256 256 256 0.450 4
P1-30 F W Q R N I R K L R -NH2 250 1,024 256 256 256 256 0.350 4
P1-31 F W Q R N I R K W R -NH2 125 512 256 256 256 256 0.5 0
P1-32 F W Q R N I R K Y R -NH2 250 512 256 256 256 256 0.5 2
P1-33 F W Q R N I R K F R -NH2 250 1,024 256 256 256 256 0.350 4
P1-34 F Y Q R N I R K V R -NH2 250 512 256 256 256 256 0.5 0
P1-35 F F Q R N I R K V R -NH2 250 512 256 256 256 256 0.5 0
P1-36 F W Q R N I R I R R -NH2 250 512 256 256 256 128 0.450 4
P1-37 F W Q R N W R K V R -NH2 250 512 256 256 256 64 0.225 8
P1-38 F W Q R N F R K V R -NH2 250 512 256 256 256 128 0.450 4
P1-39 F W Q R N Y R K V R -NH2 250 512 256 256 256 256 0.5 2
P1-40 F W Q R N I F K V R -NH2 250 1,024 256 256 256 256 0.5 0
P1-41 F W Q R N I Y K V R -NH2 250 1,024 256 256 256 256 0.5 0
P1-42 F A W Q R N I R K V R -NH2 250 1,024 256 256 256 256 0.300 4
P1-43 F I W Q R N I R K V R -NH2 250 1,024 256 256 256 256 0.350 4
P1-44 F L W Q R N I R K V R -NH2 250 1,024 256 256 256 128 0.225 8
P1-45 F V W A R N I R K V R -NH2 250 1,024 256 256 256 256 0.350 4
P1-46 F W A R N I R K V R -NH2 250 1,024 256 256 256 128 0.225 8
P1-47 F W I R N I R K V R -NH2 250 1,024 256 256 128 32 0.131 32
P1-48 F W L R N I R K V R -NH2 250 1,024 256 128 32 4 0.131 256
P1-49 F W V R N I R K V R -NH2 250 1,024 256 256 256 128 0.225 8
P1-50 F W P R N I R K V R -NH2 250 1,024 256 256 256 32 0.131 32
P1-51 F W Q R P I R K V R -NH2 250 1,024 256 256 128 64 0.163 16
P1-52 F W Q R G I R K V R -NH2 250 1,024 256 256 256 128 0.225 8
P1-53 F W Q S N I R K V R -NH2 250 1,024 256 256 256 256 0.5 0
P1-54 F W Q R N I S K V R -NH2 250 512 256 256 256 256 0.5 0
P1-55 F W Q R N I R S V R -NH2 250 512 256 256 256 256 0.5 0
P1-56 F W Q R N I R K V S -NH2 250 512 256 256 256 256 0.5 0
a MIC of the antibiotic determined by a microbroth-based assay in non-cation-adjusted Mueller-Hinton medium.
b Fractional inhibitory concentration (FIC) index (see Materials and Methods for details). FIC indices indicative of synergy are shown in boldface.
c Ratio of antibiotic MICs (determined as described in footnote a) in the absence and in the presence of the peptide. The ratio shown is the maximum value of those
calculated for each peptide concentration. MIC ratios indicative of synergy are shown in boldface.
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Combined therapy in vivo. Female ICR (CD-1) mice weighing 20 to 23 g were
purchased from Harlan Spain (Harlan Interfauna Iberica S.A., Barcelona, Spain)
and randomly distributed in experimental groups (n  16). Animals were im-
munosuppressed by the subcutaneous administration of two doses of cyclophos-
phamide 4 days before (3 mg/animal) and 1 day before (2 mg/animal) bacterial
inoculation. In preliminary experiments, this treatment was shown to cause
severe neutropenia (PMN  1,000) in the animals 24 h after the second admin-
istration of the immunosuppressant. Inocula for experimental infections con-
sisted of 105 CFU of Pseudomonas aeruginosa PAO1 administered intraperito-
neally. In pilot experiments, this dose was found to be lethal for more than 90%
of the animals at day 2 postinoculation. One hour after bacterial inoculation, a
group of animals was intraperitoneally injected with a combination of 500 g of
the test peptide (25 mg/kg of body weight) and 500 g of erythromycin resus-
pended in 200 l of saline. Animal mortality was monitored at daily intervals for
7 days. In parallel experiments, a group of animals received a second dose of the
combined treatment by the same route 5 h after the first dose administration. As
controls for these experiments, a group of PAO1-inoculated animals was treated
either with 500 g of the peptide or with 500 g of the antibiotic alone. Finally,
one experimental group inoculated with bacteria was left untreated. The results
of animal mortality at all experimental time points were analyzed using the
Kaplan-Meier survival analysis. When the survival plots were parallel, data were
compared by the log rank test, whereas for those plots that intersected, the
Breslow-Gehan-Wilcoxon test was applied. P values were always obtained by
comparing data from the same experiment (mortality in treated versus un-
treated groups). All the mouse experiments were approved by the Ethical
Committee for Animal Experimentation of the University of Navarra (per-
mission number 069/09).
Calculation of peptide descriptors. Peptide descriptors were calculated using
in-house PEDES (peptide descriptors from sequence) computer software (24)
(see the supplemental material). The PEDES algorithm calculates composition
and sequence-dependent physicochemical descriptors based entirely on the pep-
tide amino acid sequence. Descriptors are based on the recapitulation of the
mechanism of the antimicrobial peptide mode of action. The PEDES output
consists of a file in which 32 descriptors are listed for each individual peptide
TABLE 3. Definitions of peptide descriptors used in the QSAR study
Type of
descriptor Abbreviation Definition
Constitutionala length No. of amino acid residues in the peptide
MW(peptide-NH2): Mol wt of the peptide
no_basic No. of basic residues
no_aromatic No. of aromatic residues
no_hydrophobic No. of hydrophobic residues
no_W No. of Trp residues
no_basic/length No. of basic residues divided by the length of the peptide (linear density
of basic residues in the sequence)
% basic_res Percentage of basic residues
% hydrophobicbasic_res Percentage of sum of hydrophobic and basic residues
sum_aromaticbasic Sum of aromatic and basic residues
He Hydrophobicity according to the Eisenberg scale (11)
Hk Hydrophobicity according to the Kyte-Doolittle scale (34)
Sequence
dependentb
max_dis_W Maximum distance between Trp residues in the sequence
max_dis_basic Maximum distance between basic residues in the sequence
max_dis_ aromatic Maximum distance between aromatic residues in the sequence
max_dis_ hydrophobic Maximum distance between hydrophobic residues in the sequence
hmom(100deg) Hydrophobic moment () at 100° angle (5/9  rad).
  
n
NHn sin	n
2  
n
NHn cos	n
21/2 where Hn is the
hydrophobicity of nth residue and 	 is the angle between two sequential
reinsured measured in radians
hmom(160deg) Hydrophobic moment () at 160° angle
hmom(180deg) Hydrophobic moment () at 180° angle
max_avg_seq_chg(frame  2) Maximum avg charge of 2 sequential residues
max_avg_seq_chg(frame  4) Maximum avg charge of 3 sequential residues
max_avg_seq_chg(frame  3) Maximum avg charge of 4 sequential residues
no_2-aromatic-res-clust No. of 2 aromatic residue clusters
no_2-hydrophobic-res-clust No. of 2 hydrophobic residue clusters
no_2-polar-res-clust No. of 2 polar residue clusters
no_2-basic-res-clust: No. of 2 basic residue clusters
max_basic_clust_chg Maximum charge of basic residue cluster
avg_dist_between_chg Avg distance between basic residues
avg_dist_hydrophobic_chg Avg distance between hydrophobic residues
(cen_pos_chg_res)-(cen_hydrophobic_res) Distance between the centers of basic and hydrophobic residues
(c.o.m._pos_chg_res)-(c.o.m._hydrophobic_res) Distance between the centers of gravity of basic and hydrophobic residues
linear_amphiphatic_moment
LAM 

i  1
N
HEisenberg i
  i

i  1
N
HEisenberg i

where i is the sequential residue no. in the
peptide from the N-terminal part and HEisenberg (i) is the
hydrophobicity, according to the Eisenberg scale
a Constitutional descriptors depend fundamentally on the amino acid composition of the peptides.
b Sequence-dependent descriptors depend more on the geometry and topology of the peptides.
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(Table 3) and a file which represents the input matrix for QSAR calculation.
Definitions of constitutional and sequence-dependent descriptors are provided
in Table 3. LogP values were calculated using HyperChem 6.0 software.
QSAR models. MIC activities against Pseudomonas aeruginosa were measured
for a set of 93 peptides, including LF11, lauryl-LF11, 56 peptides from the first
generation, and 35 peptides from the second generation. Experimental data were
filtered by including only exact values and excluding all nondetermined values
(e.g., MIC  250 g/ml). This condition reduced the original set of 93 peptides
to 30 peptides for MIC activities, 53 for novobiocin MIC ratios, and 51 for FIC
values.
For series of peptides with the same mode of action, it can be shown that the
biological activity of a peptide, i, can be written as a linear combination of
physicochemical descriptors, as follows:
log
1
BAt
 a1P1i
 a2P2i
 . . . amPmi
 C
where m is the number of independent physicochemical parameters, Pj(i) is the
jth parameter of the peptide i, BAi is the measurement of the biological activity
that is expressed as the 50% inhibitory concentration (IC50) or MIC, and aj is the
coefficient in the multiple linear equation corresponding to the parameter Pj(i)
(49). Biological activity was modeled with PLS (partial least-squares projection
to latent structures) analysis using CODESSA software (32). Peptide descriptors
were centered and normalized prior to analysis to ensure that they had equal
influence in the model.
RESULTS
Characterization of mechanisms of antibiotic resistance. To
study to what extent the mechanisms of antibiotic resistance
expressed by Pseudomonas aeruginosa can be neutralized by
peptide-mediated permeabilization, we first characterized the
most relevant mechanisms of antibiotic resistance in a collec-
tion of clinical strains with distinct antibiotic susceptibility pro-
files. Specifically, we studied the presence of representatives of
the major classes of antibiotic resistance mechanisms such as
(i) systems involved in the active efflux of antibiotics (i.e., Mex
family), (ii) repression of porins mediating antibiotic entry
(i.e., OprD for imipenem), (iii) modifications in the intracel-
lular antibiotic target (i.e., quinolone resistance-determining
region [QRDR] of gyrase for quinolones), and (iv) production
of hydrolytic enzymes (AmpC and carbapenemase production
for beta-lactam antibiotics). As controls for these studies, we
included nalB and oprD mutant derivatives of the wild-type P.
aeruginosa PAO1 strain.
The strains chosen for this study expressed different antibi-
otic resistance mechanisms (Table 1), and each pattern was
associated with a distinct profile of antibiotic susceptibility
(data not shown). This characterization provided us with a
means to infer the sensitivity of each particular combination of
mechanisms to peptide-mediated permeabilization.
Quantification of the permeabilizing activity of the peptides.
Using P. aeruginosa Ps4 as a test strain, we studied the ability
of the compounds from a peptide library derived from human
lactoferricin (53) to sensitize P. aeruginosa to novobiocin, a
hydrophobic antibiotic that cannot reach its intracellular target
(gyrase) due to its inability to cross the intact outer membrane.
To quantify the existence of synergy, we calculated the ratio of
novobiocin MICs in the absence (MIC 512 g/ml) and in the
presence of subinhibitory concentrations of the peptides (MIC
ratio). To correct for the differences in peptides’ MICs, we also
calculated the FIC indices for all the peptide-novobiocin com-
binations (Table 2). The majority of authors consider a com-
bination synergistic when its FIC index is 0.5 or when the
MIC ratio is at least 4 (13).
Based on those criteria, most of the peptides (36 of 56) acted
in synergy with novobiocin, and in all cases, the two parameters
used to detect synergy were in agreement. However, the infor-
mation provided by FIC indices and MIC ratios was not quan-
titatively comparable (Table 2). Based on these results and
other comparative physical data (not shown), a second set of
peptides was generated (called second-generation peptides).
QSAR model of the antibiotic-enhancing activity of pep-
tides. We hypothesized that we could predict the permeabiliz-
ing activity of the new generation of peptides based on the
novobiocin-enhancing activity of the first generation of pep-
tides (henceforth second and first generation, respectively). To
correlate physicochemical properties to biological activity, we
performed a QSAR analysis using experimentally determined
biological data, including antimicrobial activity, affinity for
LPS, and structural data based on determined tertiary struc-
tures, and combined it with partial least-squares regression
(also known as partial least-squares projection to latent struc-
tures [PLS]). Since peptides are highly difficult to treat using a
conventional QSAR approach due to their complex structure
soft-modeling PLS, we devised a new set of 32 structural and
constitutional parameters called PEDES. These parameters
describe physicochemical properties of the peptides mechanis-
tically related to their antimicrobial and permeabilizing activ-
ities (Table 3), as detailed in Materials and Methods.
Peptide descriptors contain both compositional and se-
quence-related information, such as the content of basic resi-
dues or the number of hydrophobic residue clusters, respec-
tively. Descriptors were arranged in the input x matrix, where
each peptide constituted a row and each descriptor constituted
a column. Similarly, MIC values (factor 1), novobiocin MIC
ratios at peptide concentrations of 50 g/ml (factor 2), and FIC
values (factor 3) were used to construct a 93-by-3 matrix.
A principal component analysis of log(1/MIC of peptide)
showed that peptides distribute into approximately three clus-
ters according to their number of basic residues (see Fig. S1b
in the supplemental material). A first cluster consisting of P1-7,
P1-15, P1-11, P1-12, and P1-19 contained peptides with five or
more basic residues. Most of the peptides which clustered
around the origin contained four basic residues, whereas P2-
23, P2-29, P2-30, and P2-31 each possessed three basic resi-
dues. In addition, each cluster could be subdivided according
to the number of hydrophobic residues. Variation in the de-
scriptors could be related to variation in MIC values in the
loading plots (see Fig. S1a in the supplemental material). Most
of the variation could be assigned to the first two principle
components, which explained 64% of the total variation. Since
peptides with lower MIC values have larger log(1/factor 1)
values, descriptors which are oriented in the same direction as
that of the log(1/factor 1) vector in the factor 1-factor 2 plane
will have an increase in antimicrobial activity, and the opposite
(mirrored through the origin) will occur to those descriptors
that are negatively correlated. The PLS-loading plot in Fig. S1a
in the supplemental material shows that the most important
descriptors governing antibacterial activity are the number of
Trp residues, hydrophobicity, the number of aromatic residues,
and the percentage of hydrophobic plus basic residues. Nega-
tive correlation was observed for the following descriptors: the
number of basic residues, maximum basic cluster charge, num-
ber of 2-polar residue clusters, and length. The success of
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QSAR analysis was confirmed by the agreement found be-
tween experimental and calculated MIC values (R2  0.94 for
the 5-parameter model), as shown in Fig. 1A. The model was
validated using leave-one-out cross-validation (CV), which
rendered an R2(CV) value of 0.90 (58).
A similar approach was used to analyze novobiocin MIC
ratios at a 50 g/ml peptide concentration and FIC data. For
novobiocin MIC ratios at a 50 g/ml peptide concentration,
PLS scores showed that peptides clustered according to their
numbers of basic residues (see Fig. S1d in the supplemental
material), in which we found a clear distinction between pep-
tides of the first and second generations, except for peptides
with the same number of cationic residues. The PLS-loading
plot in Fig. S1c in the supplemental material revealed a posi-
tive correlation between log(1/factor 2) and the following de-
scriptors: the number of Trp, the hydrophobic moment, the
maximum distance between aromatic residues, and hydropho-
bicity. A negative correlation was found between log(1/factor
2) and length, molecular weight (MW), maximum basic cluster
charge, maximum average sequential charge, and the number
of two basic residue clusters. The model which contained five
significant components (factors 1, 3, 4, 5, and 23) explained
85% of the variation and showed good agreement with exper-
imental data (R2  0.838) (Fig. 1B). The most important pa-
rameters that positively correlated with factor 3 were the hy-
drophobic moment, basic residue density (the number of basic
residues/length), and the number of basic residues (see Fig.
S1e in the supplemental material), whereas negative correla-
tion was observed in terms of the number of hydrophobic
residues and hydrophobicity, suggesting that charge plays an
important role in FIC activity. The PLS regression model is
shown in Fig. 1C (R2  0.844).
To test the validity of our QSAR analysis, we used the PLS
models to predict the permeabilizing activity of the second
generation of peptides. In parallel, we quantified the novobio-
cin-enhancing activity of the new peptide generation, as ex-
pressed by their MIC ratios and FIC indices. The results from
these assays are shown in Table 4, along with the relative
position that each compound occupies in the ranking of per-
meability-enhancing activity, according to our predictions. Al-
most all the compounds with significant permeabilizing activity
were correctly predicted to rank among the first two groups,
whereas those peptides lacking novobiocin-potentiating activ-
ity fell into the third and fourth groups, with a few exceptions.
More importantly, the predicted MIC ratios were found to
correlate with the corresponding experimental values to a large
extent (Spearman’s   0.74; P  0.001). These experiments
led to the selection of two of the most potent permeabilizing
compounds, P2-15 and P2-27, for the following assays.
Neutralization of P. aeruginosa resistance mechanisms. To
study to what extent lactoferricin-derived peptides could neu-
tralize antibiotic resistance mechanisms expressed by P. aerugi-
nosa, we combined either P2-15 or P2-27 with representatives
of antibiotic classes differing in their mechanism of action. For
these experiments, synergy was assessed by the checkerboard
assay, using the P. aeruginosa strains whose antibiotic resis-
tance mechanisms had been previously characterized as test
organisms (Table 1). As shown in Table 5, subinhibitory con-
centrations of P2-15 or P2-27 sensitized wild-type strain PAO1
to several antibiotics, including a macrolide (erythromycin), a
quinolone (nalidixic acid), chloramphenicol, and fusidic acid.
Peptides also acted in synergy (FIC indices  0.5) with beta-
lactamic antibiotics, but sensitization was more modest than
that measured for the previous antibiotics (examples shown in
Table 5). P2-15 and P2-27 were able to counteract efflux pump
FIG. 1. Partial least-squares projection to latent structures (PLS)
analysis of the correlation between descriptors and antimicrobial ac-
tivities, expressed as MIC values (A), novobiocin MIC ratio values at
a 50 g/ml peptide concentration (B), and FIC values (C) against P.
aeruginosa. Models illustrating the correlation between experimental
and calculated values are shown.
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overexpression when tested with strain PAOLC1-6, since they
formed synergistic combinations with antibiotics that are
known substrates of the MexAB-OprM system, with the excep-
tion of cefotaxime. In addition, both peptides efficiently sensi-
tized strain TNP004, an isogenic PAO1 mutant lacking the
imipenem-specific OprD porin, to imipenem, demonstrating
that this mechanism is susceptible to peptide-mediated perme-
abilization. Similar results were obtained with the P. aeruginosa
Ps21 and Ps64 clinical strains that not only lack OprD but also
express other mechanisms contributing to imipenem resis-
tance, such as AmpC constitutive derepression in the former
strain and global efflux pump overexpression in the latter
strain. In contrast, even the most potent peptide P2-15 was
barely able to neutralize a mechanism of carbapenem resis-
tance based, at least partially, on carbapenemase expression
(see results from strain Ps71 in the presence of imipenem or
meropenem). This phenomenon resembles the one mentioned
above for AmpC, another antibiotic-hydrolyzing enzyme. Nev-
ertheless, the clinical strain opposing the highest resistance to
peptide-mediated permeabilization was, not unexpectedly, the
one displaying peptide insensitivity, as observed with the colis-
tin-resistant strain Ps74.
Peptides had varied success with sensitizing quinolone-resis-
tant clinical strains, such as Ps1 and Ps6, to quinolones, and
this appeared to depend on the profile of resistance mecha-
nisms displayed by the organism. Thus, at low peptide concen-
trations, strain Ps6 was harder to sensitize to nalidixic acid than
Ps1. This may be due to the interplay of generalized global
efflux pump overexpression and the presence of modifications
at the QRDR site in the former strain (Table 1). In contrast,
none of the peptides could neutralize the mechanisms impli-
cated in resistance to ciprofloxacin.
Our control permeability-increasing agent, PMBN, clearly
outperformed our peptides in almost all the cases and
strongly sensitized P. aeruginosa strains even to beta-lac-
tamic antibiotics and ciprofloxacin, although it failed to
TABLE 4. Novobiocin-enhancing activity of second-generation peptides on P. aeruginosa Ps4f
Peptide Sequence MIC(g/ml)a
Novobiocin MIC at indicated peptide
concn (g/ml)e FICb MICratioc
Predicted
MIC ratio
(group)d0 6.25 12.5 25 50
P2-1 F W Q R N I R I R R -NH2 250 1,024 256 256 256 256 0.5 0 3
P2-2 L W Q R N I R I R R -NH2 250 1,024 256 256 256 256 0.5 0 3
P2-3 I W Q R N I R I R R -NH2 250 1,024 256 256 256 256 0.5 0 3
P2-4 F F W Q R N I R I R R -NH2 250 1,024 256 256 256 256 0.5 0 3
P2-5 F W Q R N W R I R R -NH2 250 1,024 256 256 256 256 0.5 0 4
P2-6 F W Q R N I R W R R -NH2 250 1,024 256 256 256 256 0.5 0 4
P2-7 F W Q R N I R F R R -NH2 250 1,024 256 256 256 256 0.5 0 4
P2-8 F W Q R N W R W R R -NH2 250 1,024 256 256 256 256 0.5 0 3
P2-9 F W Q R N W R F R R -NH2 250 1,024 256 256 256 256 0.5 0 4
P2-10 F W R N I R I R R -NH2 250 1,024 256 256 256 128 0.23 8 2
P2-11 F W R N I R I R R -NH2 125 1,024 256 256 256 8 0.408 128 2
P2-12 F W G R N I R I R R -NH2 250 1,024 256 256 256 128 0.225 8 2
P2-13 F W Q R I R I R R -NH2 250 1,024 256 256 256 128 0.225 8 2
P2-14 F W Q R N L R L R R -NH2 250 1,024 256 256 256 256 0.5 0 4
P2-15 F W R I R I R R -NH2 62,5 1,024 256 16 2 NG 0.216 4,096 1
P2-16 F W R N I R I W R R -NH2 250 1,024 256 256 16 2 0.116 512 3
P2-17 F W Q R N W I R R -NH2 250 1,024 256 256 256 256 0.5 0 4
P2-18 R F W Q R N I R I R R -NH2 250 1,024 256 256 256 256 0.5 0 2
P2-19 R W Q R N I R I R R -NH2 250 1,024 256 256 256 256 0.5 0 2
P2-20 F W Q R N I R F V R -NH2 250 1,024 256 256 256 256 0.5 0 4
P2-21 F W Q R N I W R R -NH2 250 1,024 256 256 256 256 0.5 0 4
P2-22 F W R R N F W R R -NH2 250 1,024 256 256 64 16 0.163 64 3
P2-23 F W R W R R -NH2 125 1,024 256 256 256 128 0.525 8 1
P2-24 F W R R W R R -NH2 125 1,024 256 256 64 4 0.263 256 1
P2-25 F W R R W I R R -NH2 125 1,024 256 32 4 0,5 0.131 2,048 1
P2-26 F W R G W R I R R -NH2 125 1,024 256 128 32 4 0.225 256 1
P2-27 F W R R F W R R -NH2 62.5 1,024 128 8 NG NG 0.208 4,096 1
P2-28 F W R W R W R -NH2 62.5 1,024 256 128 8 1 0.325 1,024 1
P2-29 F W R I W R W R -NH2 31.25 1,024 256 256 1 NG 0.5 4,096 2
P2-30 F W R W R I W R -NH2 31.25 1,024 256 256 2 0,25 0.5 4,096 2
P2-31 F W R I W R I W R -NH2 62.5 1,024 256 256 256 NG 0.5 0 3
P2-32 F I W R W R W R -NH2 62.5 1,024 256 256 256 NG 0.5 0 2
P2-33 P F W R I R I R R -NH2 62.5 1,024 128 32 8 1 0.225 1,024 1
P2-34 F W Q R R I R I R R -NH2 250 1,024 256 256 256 128 0.225 8 1
P2-35 F Q W Q R N I R I R R -NH2 250 1,024 256 256 256 256 0.5 0 4
a MIC of the antibiotic determined by a microbroth-based assay in non-cation-adjusted Mueller-Hinton medium.
b Fractional inhibitory concentration (FIC) index (see Materials and Methods for details).
c Ratio of antibiotic MICs (determined as described in footnote a) in the absence and in the presence of the peptide.
d Classification of the peptide according to its predicted FIC index into 4 groups. Group 1, 25% of highest values; group 2, 50 to 75% of highest values; group 3, 50
to 25% of lowest values; group 4, 25% of lowest values.
e NG, no growth in a control well treated with the peptide alone, thus indicating inhibitory activity of the peptide by itself at that concentration.
f Activity observed versus activity predicted by QSAR analysis of the previous peptide generation.
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counteract imipenem resistance in the carbapenemase-ex-
pressing strain Ps71.
Peptide cytotoxicity. Before performing in vivo experiments,
we measured the cytotoxicity of the peptides on a human
culture cell line (HeLa cells) by using two complementary
assays, the neutral red and the 3-(4,5-dimethyl-2-thiazolyl)-2,5-
diphenyl-2H-tetrazolium bromide (MTT) tests. As shown in
Table 6, neither P2-15 nor P2-27 significantly reduced cell
viability when tested by the MTT assay at 100 g/ml, a con-
centration almost double their MICs and at least 10 times
higher than their minimum permeabilizing activity levels. In
contrast, PMB was notably more cytotoxic under the same
conditions and reduced cell viability to 54%. Unlike the
MTT test, which measures the cell respiratory rate, the
neutral red assay detects alteration of the cell membrane. As
judged by the latter assay, P2-15 was less cytotoxic than
P2-27 and PMB.
Peptide-mediated antibiotic-enhancing activity in vivo.
Based on its low toxicity and high permeabilizing activity in
vitro, we selected compound P2-15 to evaluate whether this
peptide could potentiate antibiotic activity in vivo. As an in-
fection model, we used mice that had been rendered neutro-
penic by treatment with cyclophosphamide. We chose this
model to try to reproduce the clinical scenario, where immu-
TABLE 5. Antibiotic-enhancing activity of peptides added at subinhibitory concentrations to P. aeruginosa strainse
Strain Antibiotic MIC(g/ml)a
P2-15 P2-27 PMBNc
MIC atb:
FICd
MIC at:
FIC
MIC at:
FIC
6.25 12.5 25 6.25 12.5 25 6.25 12.5 25
PAO1 Erythromycin 128 16 8 1 0.325 16 2 NG 0.325 0.25 0.25 NG 0.052
Fusidic acid 1,024 64 8 0.5 0.263 32 8 1 0.231 0.5 0.5 0.5 0.050
Nalidixic acid 512 32 8 0.5 0.263 32 16 1 0.263 1 0.5 0.5 0.058
Chloramphenicol 256 16 8 1 0.225 8 1 0.25 0.231 1 1 1 0.066
Amoxicillin 2,048 256 128 32 0.325 512 128 32 0.350 2 1 1 0.052
Ampicillin 1,024 256 32 8 0.431 512 32 NG 0.431 16 8 4 0.066
PAOLC1-6 (nalB) Tetracycline 32 4 4 1 0.325 8 4 NG 0.350 2 2 2 0.081
Fusidic acid 4,096 1,024 128 16 0.431 1,024 32 4 0.408 1 1 1 0.050
Nalidixic acid 1,024 256 32 4 0.431 16 8 4 0.216 4 2 2 0.066
Chloramphenicol 256 8 8 0.25 0.163 4 2 2 0.163 4 4 4 0.066
Cefotaxime 64 16 16 8 0.650 32 16 NG 0.550 2 2 1 0.081
Ticarcillin 64 32 8 4 0.525 16 16 4 0.350 1 0.12 0.12 0.081
TNP004 (oprD) Imipenem 8 2 0.5 0.12 0.450 2 2 0.25 0.350 0.125 0.12 0.12 0.066
Ps2 Imipenem 32 32 32 8 0.350 32 16 16 0.550 2 2 1 0.131
Meropenem 8 4 2 2 0.350 16 8 4 0.6 1 1 0.5 0.07
Ps21 Imipenem 64 32 16 2 0.231 64 16 8 0.325 0.125 0.063 0.06 0.116
Meropenem 32 16 8 4 0.325 16 8 8 0.350 1 0.125 0.125 0.163
Ps64 Imipenem 16 4 4 2 0.225 8 8 8 0.525 0.06 0.06 0.06 0.011
Meropenem 32 16 8 4 0.175 16 8 4 0.175 0.06 0.06 0.06 0.005
Ps71 Imipenem 16 16 16 0.5 0.431 16 16 16 1.003 16 8 8 0.600
Meropenem 32 16 8 2 0.450 32 32 32 1.003 8 2 2 0.163
Ps74 Imipenem 32 32 32 32 1.003 32 32 32 1.003 8 8 2 0.350
Meropenem 8 8 4 4 0.525 8 8 4 0.550 1 1 0.25 0.250
Ps1 Nalidixic acid 2,048 64 32 16 0.16 128 64 32 0.23 64 32 8 0.06
Ciprofloxacin 128 32 32 16 0.65 32 32 32 0.65 16 16 8 0.28
Ps6 Nalidixic acid 2,048 512 64 8 0.43 512 128 32 0.45 32 32 ND 0.21
Ciprofloxacin 128 32 32 16 0.65 32 32 16 0.65 16 16 8 0.28
a MIC of the antibiotic determined by a microbroth-based assay in non-cation-adjusted Mueller-Hinton medium.
b MICs are given for antibiotics in the presence of the indicated subinhibitory concentrations (g/ml) of peptides P2-15, P2-27, and PMBN. The MICs of all the
peptides on most of the strains were 31.25 to 64.5 g/ml. Strains Ps21, Ps2, Ps64, and Ps74, in that order, were the most resistant (MICs of 125 to 250 mg/ml).
c Polymyxin B nonapeptide.
d Fractional inhibitory concentration (FIC) index (see Materials and Methods for details).
e ND, not determined; NG, no growth in a control well treated with the peptide alone, thus indicating inhibitory activity of the peptide by itself at that concentration.
TABLE 6. Cytotoxicity of selected peptides on human cellsa
Compound
Cytotoxicity results
Neutral red test MTT test
P2-15 93.7  18.3 97.5  11.2
P2-27 80.9  5.9 99.1  9.8
P2-29 87.3  0.1 53.7  8.0
DMSOb 4.2  2.1 1.3  3.5
Melittin 12.8  11.9 9.9  0.6
Polymyxin B 75.5  10.2 54.2  12.0
a Cells were exposed to 100 g/ml of the indicated compound for 60 min.
Results are expressed as the percentages of cell viability  standard deviations,
with respect to an untreated control (100%).
b Treatment with dimethyl sulfoxide (DMSO; 100 g/ml) was used as a posi-
tive control of toxicity.
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nocompromised patients are precisely the most common P.
aeruginosa hosts. We combined P2-15 with erythromycin, an
antibiotic with very low activity against P. aeruginosa (MIC 
128 g/ml) but which was efficiently potentiated in vitro
(MIC  1 g/ml) in the presence of subinhibitory amounts (25
g/ml) of P2-15. As shown in Fig. 2A, administration of either
the peptide (0.5 mg/animal intraperitoneally [i.p.]) or the an-
tibiotic (0.5 mg/animal i.p.) at 45 to 60 min postinoculation
conferred no protection to the P. aeruginosa PAO1-infected
mice. In addition, animals receiving a second dose of the same
compound 5 h after the first dose were equally unprotected. In
contrast, when P2-15 and erythromycin were given to the an-
imals (0.5 mg of each per animal i.p.) as a combined treatment
(Fig. 2B), 50% of the animals were significantly (P  0.024)
protected, although such protection was short lasting (24 h).
Interestingly, administration of a second dose of the combined
treatment 5 h after the first dose afforded long-lasting (7 days,
at least) protection to 33% of the mice (P  0.027).
DISCUSSION
This study identified peptides that efficiently permeabilize
the P. aeruginosa OM and sensitize this organism not only to
hydrophobic antibiotics (i.e., erythromycin and fusidic acid)
but also to much more hydrophilic drugs, such as the beta-
lactams amoxicillin, ampicillin, imipenem, and meropenem.
Whereas the capacity of cationic peptides of diverse natures to
enhance the activity of hydrophobic antibiotics has been re-
peatedly shown (23, 44, 61, 62), references of peptides en-
dowed with the latter ability are more scarce (18, 59). In fact,
polycations acting in synergy with hydrophobic antibiotics of-
ten fail to enhance beta-lactams on P. aeruginosa (17, 47, 56).
Our results obtained from using the wild-type strain indicate
that mechanisms of antibiotic resistance relying on the basal
activity of the efflux system in conjunction with the OM intrin-
sic permeability barrier are susceptible to peptide permeabili-
zation. Thus, when peptides were combined with either nali-
dixic acid or chloramphenicol, two known substrates of the
MexAB-OprM efflux system, MICs dropped down to levels as
low as those obtained for these antibiotics with an isogenic
mutant of PAO1 lacking the MexAB-OprM system (strain
K1119) (data not shown). In addition, peptides enhanced to
even a further extent the activity of erythromycin, novobiocin,
and fusidic acid, which are also substrates of the MexAB-
OprM system, resulting in MIC values 8 times lower than those
obtained for the same antibiotics with strain K1119. This ob-
servation implies that peptides counteract not only efflux pump
activity but also the resistance mechanism based on intrinsic low
OM permeability. Nevertheless, peptides potentiated the beta-
lactams amoxicillin and ampicillin to a lesser extent than the other
antibiotics tested, suggesting that the mechanisms providing P.
aeruginosa PAO1 with intrinsic antibiotic resistance (involved in
resistance to the latter classes of antibiotics) are more vulnerable
to permeabilization than those relying on the beta-lactamase ac-
tivity of AmpC (Table 1, profile of strain PAO1).
Using strain PAOLC1-6, we also showed that mechanisms of
resistance based on overexpression of the MexAB-OprM efflux
system are vulnerable to peptides, at least partially. Thus, pep-
tides potentiated the antibiotics tested—all of them substrates
of the MexAB-OprM system, except the most hydrophilic
ones, the beta-lactams cefotaxime and ticarcillin. It has been
hypothesized that the ability of lactoferricin to counteract ef-
flux pump activity is due not only to its membrane-disorganiz-
ing nature but also to dissipation of the proton-motive force,
resulting in decreased activity of ATP-dependent multidrug
efflux pumps (63). The latter activity has also been reported in
peptides unrelated to lactoferricin (51). Interestingly, unlike
P2-15 and P2-27, the first-generation peptide P1-22 was unable
to sensitize strain PAOLC1-6 to antibiotics (53).
In contrast to the susceptibility to the previous mechanisms,
strains carrying mutations in the binding sites of quinolones were
not vulnerable to permeabilization. In these strains, it is likely that
the antibiotic does not reach an intracellular concentration high
enough to compensate for the loss of affinity of its target mole-
cule, gyrase, and topoisomerase, as previously suggested (7).
While considerable effort to study how to rationally improve
the antibacterial activity and selectivity of AMPs has been
made (2, 8, 14, 15, 16, 26, 28, 29, 30, 31, 45, 48, 50), to our
knowledge, this is the first report investigating the structural basis
FIG. 2. Therapeutic efficacy of a peptide-antibiotic combination
against an intraperitoneal infection of P. aeruginosa PAO1. Prior to
infection, groups (n  16) of mice were rendered neutropenic (immu-
nocompromised) by the subcutaneous administration of two doses of
cyclophosphamide. On day 0, mice were i.p. infected with 105 CFU per
animal, and 60 min later, they i.p. received the following treatment:
either a single dose of the peptide P2-15 or erythromycin (0.5 mg/
animal in both cases) (A) or a combination of the peptide and the
antibiotic administered at the same concentration as that used in the
single-dose treatment (B). Groups of animals received second doses of
the corresponding treatment 5 h after the first doses. Statistical differ-
ences were analyzed by the Kaplan-Meier survival test (*, P  0.05).
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of peptide-mediated OM permeabilization as a function of the
peptide’s ability to enhance antibiotic activity. In this regard, our
results confirm (53, 56, 64) that antibacterial activity and antibi-
otic-enhancing ability are not necessarily associated, since pep-
tides with poor antimicrobial activity levels showed significant
novobiocin-enhancing potential (e.g., compounds P1-14 and P1-
48). This behavior resembles that of compounds such as PMBN
(59) and CEMA (cecropin A-melittin hybrid peptide) (46).
Conversely, some peptides with high antimicrobial activity
levels were barely able to act in synergy with novobiocin (e.g.,
P1-22, P2-29 and P2-30), a result in agreement with that of
previous authors (36, 55), who reported that the lethal (bacte-
ricidal) activity of a compound may be so great that it is not
possible to observe nonlethal (permeabilization) activity. A
similar explanation of this phenomenon was given by Zhang
and collaborators, who proposed that the highly bactericidal
peptides cannot exhibit synergy because they cause cell death
at the same concentration at which they permeabilize the OM
(64). Finally, we showed that it is possible to design potent
permeabilizers that rank among the best antibacterial agents,
as exemplified by our lead compounds P2-15 and P2-27.
The correlation found between the predicted parameters
and the corresponding experimental values confirm the utility
of the QSAR-PLS analysis. In this regard, our results confirm
that to maximize antimicrobial activity against Gram-negative
bacteria, it is favorable to have larger amounts of hydrophobic
residues, which cause distortions in the membrane (12, 21, 22).
On the other hand, activity is decreased by an excessive con-
centration of basic residues in the molecule and by large pep-
tide size, with the latter factor probably reflecting the steric
hindrance that high-molecular weight peptides will encounter
when crossing the hydrophilic carbohydrate chains of LPS (1).
Regarding permeabilizing activity, positive and negative corre-
lations observed between FIC/MIC ratios and several parameters
indicate that a high localization of charge (two or more sequential
basic residues in the sequence) reduces synergistic activity. Ac-
cording to this model, the peptides should have larger amounts of
aromatic residues, amphiphilic structure, and lower localization
of positively charged residues to achieve optimal activity. Recent
studies support the importance of some of these parameters, such
as aromatic residues, in permeabilizing activity (10). These con-
clusions are consistent with the notion that the dual nature (cat-
ionic and hydrophobic) of a peptide is the driving force for its
initial interaction with the OM (1).
Several QSAR studies correlating the antimicrobial activi-
ties of AMPs to their structural properties were recently pub-
lished (8, 14, 15, 16, 26, 28, 29, 31, 45). The strategies used in
those reports to build mathematical models include artificial
neural networks, PLS-based methods, k-nearest neighbor anal-
ysis, and multiple linear regression. In these studies, structural
properties of the peptides are presented as physicochemical
descriptors. Ideally, these descriptors are calculated from
three-dimensional models, but since a very limited number of
structures is available (e.g., from nuclear magnetic resonance
studies), in most cases, homology modeling is used to infer the
required structures. The main disadvantage of this approach is
that small changes in peptide sequence can drastically affect
structure (20, 27, 28). Moreover, peptide conformation can be
strongly influenced by binding to different structures of the
bacterial membrane (lipopolysaccharide and phospholipids)
unless stabilized by covalent bonds (4, 25). The main advantage
of the PEDES (peptide descriptors from sequence) methodol-
ogy is—as the name suggests—that it avoids structure-related
descriptors by using a set of constitutional and sequence-de-
pendent descriptors based on amino acid sequence. These de-
scriptors were deduced from previous QSAR studies of lacto-
ferricin-derived AMPs (21, 22, 57). As illustrated in this study,
PEDES methodology offers a rapid and robust alternative for the
calculation of descriptors which can then be analyzed using the
PLS method to successfully predict activities of related AMPs.
Finally, although the ability of our leading peptide to en-
hance erythromycin activity in vivo and to protect animals from
a lethal infection is far from optimal, it demonstrates the ther-
apeutic potential of our compounds. Further studies are in
progress to improve the efficiency of the experimental treat-
ment and to rationally design new generations of peptides with
enhanced permeabilizing activity by applying the conclusions
of our QSAR analysis.
ACKNOWLEDGMENTS
We are grateful to M. Carmen Conejo, Luis Martínez-Martínez, and
Alvaro Pascual (from the Department of Microbiology, University of
Seville, Spain) for providing us with strain PAOLC1-6.
G.M.d.T. was funded by grants from Ministerio de Sanidad y Con-
sumo (FIS-PI050768), Spain, and from Proyectos de Investigacio´n
Universidad de Navarra (PIUNA-2008-11), Spain. The study has been
carried out with financial support from the Commission of the Euro-
pean Communities, specific RTD program “Quality of Life and Man-
agement of Living Resources,” QLCK2-CT-2002-01001, “Antimicro-
bial Endotoxin Neutralizing Peptides To Combat Infectious Diseases.”
REFERENCES
1. Andra¨, J., K. Lohner, S. E. Blondelle, R. Jerala, I. Moriyon, M. H. Koch, P.
Garidel, and K. Brandenburg. 2005. Enhancement of endotoxin neutraliza-
tion by coupling of a C12-alkyl chain to a lactoferricin-derived peptide.
Biochem. J. 385:135–143.
2. Andra¨, J., D. Monreal, G. Martinez de Tejada, C. Olak, G. Brezesinski, S.
Sanchez-Gomez, T. Goldmann, R. Bartels, K. Brandenburg, and I. Moriyon.
2007. Rationale for the design of shortened derivatives of the NK-lysin-
derived antimicrobial peptide NK-2 with improved activity against gram-
negative pathogens. J. Biol. Chem. 282:14719–14728.
3. Balakrishna, R., S. J. Wood, T. B. Nguyen, K. A. Miller, E. V. Suresh Kumar,
A. Datta, and S. A. David. 2006. Structural correlates of antibacterial and
membrane-permeabilizing activities in acylpolyamines. Antimicrob. Agents
Chemother. 50:852–861.
4. Berman, H. M., J. Westbrook, Z. Feng, G. Gilliland, T. N. Bhat, H. Weissig,
I. N. Shindyalov, and P. E. Bourne. 2000. The Protein Data Bank. Nucleic
Acids Res. 28:235–242.
5. Bonomo, R. A., and D. Szabo. 2006. Mechanisms of multidrug resistance in
Acinetobacter species and Pseudomonas aeruginosa. Clin. Infect. Dis.
43(Suppl. 2):S49–S56.
6. Brogden, K. A. 2005. Antimicrobial peptides: pore formers or metabolic
inhibitors in bacteria? Nat. Rev. Microbiol. 3:238–250.
7. Campos, M. A., P. Morey, and J. A. Bengoechea. 2006. Quinolones sensitize
gram-negative bacteria to antimicrobial peptides. Antimicrob. Agents Che-
mother. 50:2361–2367.
8. Cherkasov, A., K. Hilpert, H. Jenssen, C. D. Fjell, M. Waldbrook, S. C.
Mullaly, R. Volkmer, and R. E. W. Hancock. 2009. Use of artificial intelli-
gence in the design of small peptide antibiotics effective against a broad
spectrum of highly antibiotic-resistant superbugs. ACS Chem. Biol. 4:65–74.
9. Delcour, A. H. 2009. Outer membrane permeability and antibiotic resistance.
Biochim. Biophys. Acta 1794:808–816.
10. Dewan, P. C., A. Anantharaman, V. S. Chauhan, and D. Sahal. 2009. Anti-
microbial action of prototypic amphipathic cationic decapeptides and their
branched dimers. Biochemistry 48:5642–5657.
11. Eisenberg, D., R. M. Weiss, and T. C. Terwilliger. 1984. The hydrophobic
moment detects periodicity in protein hydrophobicity. Proc. Natl. Acad. Sci.
U. S. A. 81:140–144.
12. Eliassen, L. T., B. E. Haug, G. Berge, and O. Rekdal. 2003. Enhanced
antitumor activity of 15-residue bovine lactoferricin derivatives containing
bulky aromatic amino acids and lipophilic N-terminal modifications. J. Pept.
Sci. 9:510–517.
VOL. 55, 2011 IMPROVING BACTERIAL CELL PERMEABILIZING PEPTIDES 227
13. Eliopoulos, G. M., and R. C. Moellering, Jr. 1996. Antimicrobial combina-
tions, p. 330–393. In V. Lorian (ed.), Antimicrobial in laboratory medicine,
4th ed. Williams and Wilkins, Baltimore, MD.
14. Fjell, C. D., H. Jenssen, K. Hilpert, W. A. Cheung, N. Pante´, R. E. W. Hancock,
and A. Cherkasov. 2009. Identification of novel antibacterial peptides by che-
moinformatics and machine learning. J. Med. Chem. 52:2006–2015.
15. Frecer, V., B. Ho, and J. L. Ding. 2004. De novo design of potent antimi-
crobial peptides. Antimicrob. Agents Chemother. 48:3349–3357.
16. Frecer, V. 2006. QSAR analysis of antimicrobial and haemolytic effects of
cyclic cationic antimicrobial peptides derived from protegrin-1. Bioorg. Med.
Chem. 14:6065–6074.
17. Giacometti, A., O. Cirioni, F. Barchiesi, M. Fortuna, and G. Scalise. 1999.
In-vitro activity of cationic peptides alone and in combination with clinically
used antimicrobial agents against Pseudomonas aeruginosa. J. Antimicrob.
Chemother. 44:641–645.
18. Giacometti, A., O. Cirioni, W. Kamysz, G. D’Amato, C. Silvestri, A. Licci, P.
Nadolski, A. Riva, J. Lukasiak, and G. Scalise. 2005. In vitro activity of
MSI-78 alone and in combination with antibiotics against bacteria respon-
sible for bloodstream infections in neutropenic patients. Int. J. Antimicrob.
Agents 26:235–240.
19. Hancock, R. E., and D. P. Speert. 2000. Antibiotic resistance in Pseudomonas
aeruginosa: mechanisms and impact on treatment. Drug Resist. Updat.
3:247–255.
20. Hancock, R. E. W., and H. G. Sahl. 2006. Antimicrobial and host-defense
peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 24:
1551–1557.
21. Haug, B. E., and J. S. Svendsen. 2001. The role of tryptophan in the anti-
bacterial activity of a 15-residue bovine lactoferricin peptide. J. Pept. Sci.
7:190–196.
22. Haug, B. E., M. L. Skar, and J. S. Svendsen. 2001. Bulky aromatic amino
acids increase the antibacterial activity of 15-residue bovine lactoferricin
derivatives. J. Pept. Sci. 7:425–432.
23. Hogg, G. M., J. G. Barr, and C. H. Webb. 1998. In-vitro activity of the
combination of colistin and rifampicin against multidrug-resistant strains of
Acinetobacter baumannii. J. Antimicrob. Chemother. 41:494–495.
24. Japelj, B. 2005. PEDES reference manual. National Institute of Chemistry,
Ljubljana, Slovenia.
25. Japelj, B., P. Pristovsek, A. Majerle, and R. Jerala. 2005. Structural origin of
endotoxin neutralization and antimicrobial activity of a lactoferrin-based
peptide. J. Biol. Chem. 280:16955–16961.
26. Jenssen, H., T. J. Gutteberg, and T. Lejon. 2005. Modelling of anti-HSV
activity of lactoferricin analogues using amino acid descriptors. J. Pept. Sci.
11:97–103.
27. Jenssen, H., P. Hamill, and R. E. Hancock. 2006. Peptide antimicrobial
agents. Clin. Microbiol. Rev. 19:491–511.
28. Jenssen, H., T. Lejon, K. Hilpert, C. D. Fjell, A. Cherkasov, and R. E. W.
Hancock. 2007. Evaluating different descriptors for model design of antimi-
crobial peptides with enhanced activity toward P. aeruginosa. Chem. Biol.
Drug Des. 70:134–142.
29. Jenssen, H., C. D. Fjell, A. Cherkasov, and R. E. W. Hancock. 2008. QSAR
modeling and computer-aided design of antimicrobial peptides. J. Pept. Sci.
14:110–114.
30. Juretic´, D., D. Vukicevic´, N. Ilic´, N. Antcheva, and A. Tossi. 2009. Compu-
tational design of highly selective antimicrobial peptides. J. Chem. Infect.
Model. 49:2873–2882.
31. Karakoc, E., S. C. Sahinalp, and A. Cherkasov. 2006. Comparative QSAR-
and fragments distribution analysis of drugs, druglikes, metabolic substances,
and antimicrobial compounds. J. Chem. Infect. Model. 46:2167–2182.
32. Katritzky, A. R., V. Lobanov, and M. Karelson. 1996. CODESSA reference
manual. University of Florida, Gainesville, FL.
33. Kwon, D. H., and C. D. Lu. 2007. Polyamine effects on antibiotic suscepti-
bility in bacteria. Antimicrob. Agents Chemother. 51:2070–2077.
34. Kyte, J., and R. F. Doolittle. 1982. A simple method for displaying the
hydropathic character of a protein. J. Mol. Biol. 157:105–132.
35. Landman, D., C. Georgescu, D. A. Martin, and J. Quale. 2008. Polymyxins
revisited. Clin. Microbiol. Rev. 21:449–465.
36. Li, C., M. R. Lewis, A. B. Gilbert, M. D. Noel, D. H. Scoville, G. W. Allman,
and P. B. Savage. 1999. Antimicrobial activities of amine- and guanidine-
functionalized cholic acid derivatives. Antimicrob. Agents Chemother. 43:
1347–1349.
37. Livermore, D. M. 2009. Has the era of untreatable infections arrived? J.
Antimicrob. Chemother. 64(Suppl. 1):i29–i36.
38. Lohner, K., and S. E. Blondelle. 2005. Molecular mechanisms of membrane
perturbation by antimicrobial peptides and the use of biophysical studies in
the design of novel peptide antibiotics. Comb. Chem. High Throughput
Screen. 8:241–256.
39. Mesaros, N., P. Nordmann, P. Ple´siat, M. Roussel-Delvallez, J. Van Eldere,
Y. Glupczynski, Y. Van Laethem, F. Jacobs, P. Lebecque, A. Malfroot, P. M.
Tulkens, and F. Van Bambeke, F. 2007. Pseudomonas aeruginosa: resistance
and therapeutic options at the turn of the new millennium. Clin. Microbiol.
Infect. 13:560–578.
40. National Committee for Clinical Laboratory Standards (NCCLS). 2003.
Methods for dilution antimicrobial susceptibility test for bacteria that grow
aerobically, sixth edition. M7-A6. National Committee for Clinical Labora-
tory Standards, Wayne, PA.
41. Nikaido, H. 2003. Molecular basis of bacterial outer membrane permeability
revisited. Microbiol. Mol. Biol. Rev. 67:593–656.
42. Nikaido, H. 2009. Multidrug resistance in bacteria. Annu. Rev. Biochem.
78:119–146.
43. Ofek, I., S. Cohen, R. Rahmani, K. Kabha, D. Tamarkin, Y. Herzig, and E.
Rubinstein. 1994. Antibacterial synergism of polymyxin B nonapeptide and
hydrophobic antibiotics in experimental gram-negative infections in mice.
Antimicrob. Agents Chemother. 38:374–377.
44. Ohta, M., H. Ito, K. Masuda, S. Tanaka, Y. Arakawa, R. Wacharotayankun,
and N. Kato. 1992. Mechanisms of antibacterial action of tachyplesins and
polyphemusins, a group of antimicrobial peptides isolated from horseshoe
crab hemocytes. Antimicrob. Agents Chemother. 36:1460–1465.
45. Ostberg, N., and Y. Kaznessis. 2005. Protegrin structure-activity relation-
ships: using homology models of synthetic sequences to determine structural
characteristics important for activity. Peptides 26:197–206.
46. Piers, K. L., M. H. Brown, and R. E. Hancock. 1994. Improvement of outer
membrane-permeabilizing and lipopolysaccharide-binding activities of an
antimicrobial cationic peptide by C-terminal modification. Antimicrob.
Agents Chemother. 38:2311–2316.
47. Plesiat, P., J. R. Aires, C. Godard, and T. Ko¨hler. 1997. Use of steroids to
monitor alterations in the outer membrane of Pseudomonas aeruginosa. J.
Bacteriol. 179:7004–7010.
48. Powers, J. P., and R. E. Hancock. 2003. The relationship between peptide
structure and antibacterial activity. Peptides 24:1681–1691.
49. Purcell, W. P., G. E. Bass, and J. M. Clayton. 1973. Strategy of drug design:
a guide to biological activity. John Wiley & Sons, New York, NY.
50. Rathinakumar, R., W. F. Walkenhorst, and W. C. Wimley. 2009. Broad-
spectrum antimicrobial peptides by rational combinatorial design and high-
throughput screening: the importance of interfacial activity. J. Am. Chem.
Soc. 131:7609–7617.
51. Rintoul, M. R., B. F. de Arcuri, R. A. Salomo´n, R. N. Farías, and R. D.
Morero. 2001. The antibacterial action of microcin J25: evidence for disrup-
tion of cytoplasmic membrane energization in Salmonella newport. FEMS
Microbiol. Lett. 204:265–270.
52. Saha, S., P. B. Savage, and M. Bal. 2008. Enhancement of the efficacy of
erythromycin in multiple antibiotic-resistant gram-negative bacterial patho-
gens. J. Appl. Microbiol. 105:822–828.
53. Sa´nchez-Go´mez, S., M. Lamata, J. Leiva, S. E. Blondelle, R. Jerala, J.
Andra¨, K. Brandenburg, K. Lohner, I. Moriyo´n, and G. Martínez-de-Tejada.
2008. Comparative analysis of selected methods for the assessment of anti-
microbial and membrane-permeabilizing activity: a case study for lactofer-
ricin derived peptides. BMC Microbiol. 8:196.
53a.Satake, S., H. Yoneyama, and T. Nakae. 1991. Role of OmpD2 and chro-
mosomal beta-lactamase in carbapenem resistance in clinical isolates of
Pseudomonas aeruginosa. J. Antimicrob. Chemother. 28:199–207.
54. Savage, P. B. 2001. Multidrug-resistant bacteria: overcoming antibiotic per-
meability barriers of gram-negative bacteria. Ann. Med. 33:167–171.
55. Savage, P. B., C. Li, U. Taotafa, B. Ding, and Q. Guan. 2002. Antibacterial
properties of cationic steroid antibiotics. FEMS Microbiol. Lett. 217:1–7.
56. Scott, M. G., H. Yan, and R. E. Hancock. 1999. Biological properties of
structurally related alpha-helical cationic antimicrobial peptides. Infect. Im-
mun. 67:2005–2009.
57. Strom, M. B., B. E. Haug, O. Rekdal, M. L. Skar, W. Stensen, and J. S.
Svendsen. 2002. Important structural featuresof 15-residue lactoferricin de-
rivatives and methods for improvement of antimicrobial activity. Biochem.
Cell Biol. 80:65–74.
58. Tian, D., P. Zhou, F. Lv, R. Song, and Z. Li. 2007. Three-dimensional
holograph vector of atomic interaction fields (3D-HoVAIF): a novel rota-
tion-translation invariant 3D structure descriptor and its applications to
peptides. J. Pept. Sci. 13:549–566.
59. Vaara, M., and T. Vaara. 1983. Polycations sensitize enteric bacteria to
antibiotics. Antimicrob. Agents Chemother. 24:107–113.
60. Vaara, M. 1992. Agents that increase the permeability of the outer mem-
brane. Microbiol. Rev. 56:395–411.
61. Vaara, M., and M. Porro. 1996. Group of peptides that act synergistically
with hydrophobic antibiotics against gram-negative enteric bacteria. Antimi-
crob. Agents Chemother. 40:1801–1805.
62. Vaara, M., J. Fox, G. Loidl, O. Siikanen, J. Apajalahti, F. Hansen, N.
Frimodt-Møller, J. Nagai, M. Takano, and T. Vaara. 2008. Novel polymyxin
derivatives carrying only three positive charges are effective antibacterial
agents. Antimicrob. Agents Chemother. 52:3229–3236.
63. Wakabayashi, H., S. Teraguchi, and Y. Tamura. 2002. Increased Staphylo-
coccus-killing activity of an antimicrobial peptide, lactoferricin B, with mi-
nocycline and monoacylglycerol. Biosci. Biotechnol. Biochem. 66:2161–2167.
64. Zhang, L., R. Benz, and R. E. Hancock. 1999. Influence of proline residues
on the antibacterial and synergistic activities of alpha-helical peptides. Bio-
chemistry 38:8102–8111.
228 SA´NCHEZ-GO´MEZ ET AL. ANTIMICROB. AGENTS CHEMOTHER.
